SAB Biotherapeutics, Inc. SEC filings SABS

SAB Biotherapeutics, Inc. has 433 filings in SEC EDGAR's recent list, going back to Dec 7, 2020. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Apr 30, 2026 Jun 18, 2026
DEF 14A Proxy statement Aug 29, 2025 Sep 26, 2025
PRE 14A Preliminary proxy statement Aug 19, 2025 Aug 19, 2025
DEF 14A Proxy statement Jun 2, 2025 Jul 17, 2025
DEF 14A Proxy statement May 30, 2024 May 22, 2024
DEF 14A Proxy statement Dec 18, 2023 Dec 18, 2023
PRE 14A Preliminary proxy statement Dec 8, 2023 Dec 8, 2023
DEFA14A Additional proxy material Nov 14, 2023 —
DEF 14A Proxy statement Oct 30, 2023 Oct 30, 2023
PRE 14A Preliminary proxy statement Oct 20, 2023 Oct 20, 2023
DEF 14A Proxy statement May 19, 2023 Jun 29, 2023
DEF 14A Proxy statement May 25, 2022 Jul 6, 2022

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SABS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Miami Beach, FL
SEC filer status
, Emerging growth company
SEC CIK
1833214
Former names
Big Cypress Acquisition Corp. (until Oct 22, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.